Pre-PROTO-PRIME: stereotactic body proton therapy to the prostate and pelvic nodes for high-risk and node-positive prostate cancer - feasibility, acute toxicity and dosimetric insights.

ABSTRACT:

Purpose

This study aimed to assess the clinical feasibility, acute toxicity, and dosimetric advantages of stereotactic body proton therapy (SBPT) to the prostate and pelvic lymph nodes in high-risk and node-positive prostate cancer.

Methods

This multicentric analysis included 26 patients treated from February 2024 to February 2025 with SBPT to the prostate and pelvis delivered in five fractions. The doses prescribed were 36.25 CGE to the prostate, 35 CGE to the gross nodes and 25 CGE to the pelvic nodal CTV. Acute genitourinary (GU) and gastrointestinal (GI) toxicities were evaluated up to three months post-treatment using CTCAE v5.0 criteria. Dosimetric parameters of SBPT plans were compared with matched photon-based SBRT plans, generated using identical datasets. Statistic

SUBMITTER: Chilukuri S 

PROVIDER: S-EPMC12719672 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature